Association Between Pioglitazone Use and Head and Neck Cancer: Population-Based Case-Control Study
Document Type
Article
Abstract
BACKGROUND: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. METHODS: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. RESULTS: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P < .001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls. CONCLUSIONS: Prior pioglitazone use was associated with oral cavity cancer.
Digital Object Identifier (DOI)
Publication Info
Published in Head & Neck, Volume 42, Issue 4, 2020, pages 653-659.
APA Citation
Yang, T., Xirasagar, S., Cheng, Y., Wu, C., Kao, Y., Shia, B., & Lin, H. (2020). Association between pioglitazone use and head and neck cancer: Population‐based case‐control study. Head & Neck, 42(4), 653–659. https://doi.org/10.1002/hed.26046
Rights
© 2019 Wiley Periodicals, Inc.